NR5A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL46200	1.00	19/20
SCHEMBL3214	0.31	3/20
SCHEMBL25777	0.83	2/20
SCHEMBL233018	0.83	2/20
SCHEMBL234615	0.83	2/20
SCHEMBL79578	0.82	2/20
SCHEMBL236438	0.82	2/20
SCHEMBL235399	0.78	2/20
SCHEMBL1296022	0.74	2/20
SCHEMBL235516	0.74	2/20
SCHEMBL1296611	0.66	2/20
SCHEMBL160176	0.63	2/20
Colfosceril Palmitate (SCHEMBL1650061)	0.61	2/20
Trifluoromethanesulfonic Acid (SCHEMBL184536)	0.57	2/20
SCHEMBL1272115	0.56	2/20
SCHEMBL3580	0.34	2/20
SCHEMBL10827	0.34	2/20
SCHEMBL14599	0.34	2/20
SCHEMBL105209	0.34	2/20
SCHEMBL24563	1.00	1/20

Clinical trials — most relevant to NR5A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills	PHASE4	COMPLETED
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
Effects of Tibolone Treatment on the Endometrium	PHASE4	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring	PHASE3	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer	PHASE2	UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies	PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia	PHASE2	RECRUITING
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Expression of Steroid Receptors in Endometrium	nan	COMPLETED
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?	nan	UNKNOWN
Early Mental Response - The EMRE Study	nan	RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Inherited Reproductive Disorders	nan	RECRUITING
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas	nan	NOT_YET_RECRUITING
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NR5A2 binder may also engage these)

Protein	Name	Similarity
P45448	—	1.000	P45448 →
Q9QWM1	—	1.000	Q9QWM1 →
O42101	—	1.000	O42101 →
P28700	—	1.000	P28700 →
Q64249	—	1.000	Q64249 →
P51129	—	1.000	P51129 →
P33242	—	1.000	P33242 →
Q90YL6	—	1.000	Q90YL6 →
P51128	—	0.999	P51128 →
P49882	—	0.999	P49882 →
P50569	—	0.999	P50569 →
RXRA	Retinoic acid receptor RXR-alpha	0.999	landscape →
P31396	—	0.999	P31396 →
P06211	—	0.998	P06211 →
P49867	—	0.998	P49867 →
A0JNE3	—	0.998	A0JNE3 →
Q90416	—	0.998	Q90416 →
Q9PU65	—	0.998	Q9PU65 →
P51448	—	0.998	P51448 →
Q6GN21	—	0.997	Q6GN21 →
F1QLY4	—	0.997	F1QLY4 →
Q0VC20	—	0.997	Q0VC20 →
P06212	—	0.997	P06212 →
Q15406	—	0.997	Q15406 →
Q95L87	—	0.997	Q95L87 →
Q21878	—	0.997	Q21878 →
O45436	—	0.997	O45436 →
Q9GKL2	—	0.997	Q9GKL2 →
Q9XYB7	—	0.997	Q9XYB7 →
P79926	—	0.997	P79926 →